A previous study has identified that suggest that increased STAT1 signaling is important in endocrine resistance and that STAT inhibitors may represent potential therapies in endocrine-resistant breast cancer (Huang et al., 2014; Chen et al., 2023). This evidence concerns the gene STAT1 and breast carcinoma.